BioPharma Drug Approval

Merz Therapeutics Receives TGA Approval for XEOMIN® in Australia

This marks a significant milestone as XEOMIN® is the first approved neurotoxin for the treatment of this condition in the Australian market. Addit...

 November 23, 2023 | News

Innovent and AnHeart's Taletrectinib NDA Accepted by China's NMPA

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality me...

 November 23, 2023 | News

Ark Biopharma's AK0610 Receives NMPA IND Approval for RSV Neutralizing Antibody

 It is anticipated to protect infants throughout an entire RSV season. ArkBio licensed the drug's intellectual properties from the Institute of Microb...

 November 23, 2023 | News

Senhwa Biosciences Granted FDA IND for Phase II Study of Silmitasertib in Viral Community-Acquired Pneumonia (CAP)

The trial is a phase II multi-center, randomized-controlled interventional prospective study, and the purpose of this trial is to investigate whether ...

 November 22, 2023 | News

IASO Bio Sets Up Global CAR-T Center in China for Global MM Patients

On June 30, 2023, the China National Medical Products Administration (NMPA) approved the marketing of Equecabtagene Autoleucel Injection (brand name: FUCAS...

 November 22, 2023 | News

KN026 was Granted Breakthrough Therapy Designation by CDE

Gastric cancer is one of the most common gastrointestinal malignancies in the world, and the number of new cases and deaths of gastric cancer in China...

 November 08, 2023 | News

Everest Medicines Receives Approval in Macau for Nefecon® in Primary IgA Nephropathy

 Everest Medicines (HKEX 1952.HK, "Everest," or the "Company"), a biopharmaceutical company focused on the development, manufacturing and commercializ...

 October 30, 2023 | News

Life Molecular Imaging and Sinotau Gain Regulatory Approval for Neuraceq® in China

Life Molecular Imaging (LMI) and Sinotau Pharmaceutical Group are pleased to announce Neuraceq® (with Chinese trade name 欧韦宁®, florbetaben F-...

 October 25, 2023 | News

Australia's Certa Therapeutics: FT011 Granted US FDA Orphan Drug Status for Systemic Sclerosis

Orphan Drug Designation is granted by the FDA to investigational therapies addressing rare medical diseases or conditions that affect fewer than 200,000 pe...

 October 24, 2023 | News

FDA Approves PENBRAYA™: First Vaccine for 5 Common Meningococcal Serogroups in Teens

PENBRAYA™ provides the broadest serogroup coverage (meningococcal groups A, B, C, W and Y) of any meningococcal vaccine available in the U.S. ...

 October 23, 2023 | News

FDA Approves Pfizer's VELSIPITY™ for Severe UC in Adults

Pfizer Inc.  announced  that the U.S. Food and Drug Administration (FDA) has approved VELSIPITY™ (etrasimod), an oral, once-daily, selectiv...

 October 16, 2023 | News

CANbridge's CAN108 (LIVMARLI®) Receives Approval in Taiwan for ALGS-Related Pruritus

CANbridge Pharmaceuticals Inc. (1228.HK), a global biopharmaceutical company, with a foundation in China, committed to the research, development ...

 October 09, 2023 | News

FDA Grants Orphan Drug Status to GC Biopharma's Thrombocytopenic Purpura Drug in South Korea

When designated as an orphan drug, there are incentives such as tax credits for clinical development costs and exemptions from PDUFA user fees Initial Pedi...

 October 06, 2023 | News

FDA Clears Transcenta for Global Phase III Trial of Osemitamab in Gastric Cancer

Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, resear...

 October 04, 2023 | News


Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close